Advantage Trust Co Invests $53,000 in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Advantage Trust Co acquired a new stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 500 shares of the medical equipment provider’s stock, valued at approximately $53,000.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Stonebridge Financial Group LLC purchased a new position in shares of Zimmer Biomet during the fourth quarter worth about $25,000. Dunhill Financial LLC grew its stake in Zimmer Biomet by 1,090.0% in the 3rd quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock worth $26,000 after buying an additional 218 shares in the last quarter. Ashton Thomas Securities LLC purchased a new position in Zimmer Biomet in the 3rd quarter worth approximately $28,000. Brooklyn Investment Group purchased a new stake in shares of Zimmer Biomet during the 3rd quarter valued at $35,000. Finally, Kentucky Trust Co purchased a new stake in shares of Zimmer Biomet during the 4th quarter valued at $39,000. 88.89% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the company. JMP Securities restated a “market outperform” rating and set a $140.00 price target on shares of Zimmer Biomet in a research report on Friday, February 7th. Royal Bank of Canada decreased their price objective on Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating on the stock in a report on Friday, February 7th. Raymond James cut their target price on Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating for the company in a research note on Friday, February 7th. Needham & Company LLC reissued a “hold” rating on shares of Zimmer Biomet in a research note on Friday, February 7th. Finally, Stifel Nicolaus increased their target price on shares of Zimmer Biomet from $130.00 to $138.00 and gave the company a “buy” rating in a report on Thursday, January 23rd. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Zimmer Biomet currently has an average rating of “Hold” and a consensus target price of $124.15.

Zimmer Biomet Stock Performance

Shares of ZBH stock opened at $104.89 on Friday. The company has a quick ratio of 0.99, a current ratio of 1.91 and a debt-to-equity ratio of 0.43. The company has a 50 day moving average price of $105.86 and a 200-day moving average price of $107.47. Zimmer Biomet Holdings, Inc. has a 52 week low of $97.69 and a 52 week high of $133.90. The firm has a market capitalization of $20.88 billion, a PE ratio of 23.57, a P/E/G ratio of 1.95 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBH) last posted its earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, topping analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same period in the prior year, the firm posted $2.20 earnings per share. As a group, equities research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Monday, December 30th were given a $0.24 dividend. The ex-dividend date was Monday, December 30th. This represents a $0.96 annualized dividend and a yield of 0.92%. Zimmer Biomet’s payout ratio is 21.57%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.